Clinical Cancer Research, Vol 3, Issue 11 2107-2113, Copyright © 1997 by American Association for Cancer Research

ARTICLES

Pharmacological and biochemical strategies to increase the accumulation of arabinofuranosylguanine triphosphatein primary human leukemia cells

CO Rodriguez Jr, JK Legha, E Estey, MJ Keating and V Gandhi
Departments of Clinical Investigation and Hematology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, USA.

Purine nucleoside phosphorylase deficiency leads to a dGTP-mediated T-lymphopenia, suggesting that an analogue of deoxyguanosine would be selectively effective in T-cell disease. 9-beta-D-Arabinofuranosylguanine (ara-G) is relatively resistant to hydrolysis by purine nucleoside phosphorylase and selectively toxic to T cells, but its low solubility has prevented its use in the clinic. 2-Amino-6-methoxy-arabinofuranosylpurine (GW506U) serves as the water-soluble prodrug for ara-G. A Phase I trial in patients with refractory hematological malignancies demonstrated that the clinical responses to this agent were directly related to the peak levels of ara-G 5'-triphosphate (ara-GTP) in target cells. The aim of the present study was to develop and test strategies to increase intracellular accumulation of ara-GTP in primary human leukemia cells of myeloid and B-lymphoid origin. Three strategies were tested. First, incubations with 100 microM ara-G for 4 h produced a linear median accumulation rate of 19 microM/h (range, 2-45 microM/h; n = 15) in lymphoid leukemia cells and 16 microM/h (range, 0.5-41 microM/h; n = 11) in myeloid leukemia cells. Saturation of ara-GTP accumulation was achieved only after 6-8 h exposure in both lymphoid and myeloid leukemia cells, suggesting a rationale for prolonged infusion. Second, a dose-dependent increase in ara-GTP accumulation was observed with incubations of 10-300 microM ara-G for 3 h. Hence, dosing regimens that achieve high plasma levels of ara-G during therapy may increase cellular levels of ara-GTP. Finally, a biochemical modulation approach using in vitro incubation of leukemia cells with 10 microM 9-beta-D-arabinofuranosyl-2-fluoroadenine for 3 h, followed by either 50 or 100 microM ara-G for 4 h, resulted in a statistically significant median 1.3-fold (range, 1.1-9.0-fold; P = 0.034) and 1. 8-fold (range, 0.9-10.6 fold; P = 0.018) increase in ara-GTP compared to cells incubated with ara-G alone. Extension of these studies to ex vivo incubations confirmed our in vitro findings. These strategies will be used in the design of clinical protocols to increase ara-GTP accumulation in leukemia cells during therapy.

This article has been cited by other articles:

				D. F Kisor Nelarabine: A Nucleoside Analog with Efficacy in T-Cell and Other Leukemias Ann. Pharmacother., June 1, 2005; 39(6): 1056 - 1063. [Abstract] [Full Text] [PDF]

				J. Kurtzberg, T.J. Ernst, M.J. Keating, V. Gandhi, J.P. Hodge, D.F. Kisor, J.J. Lager, C. Stephens, J. Levin, T. Krenitsky, et al. Phase I Study of 506U78 Administered on a Consecutive 5-Day Schedule in Children and Adults With Refractory Hematologic Malignancies J. Clin. Oncol., May 20, 2005; 23(15): 3396 - 3403. [Abstract] [Full Text] [PDF]

				C. O. Rodriguez Jr., B. S. Mitchell, M. Ayres, S. Eriksson, and V. Gandhi Arabinosylguanine Is Phosphorylated by Both Cytoplasmic Deoxycytidine Kinase and Mitochondrial Deoxyguanosine Kinase Cancer Res., June 1, 2002; 62(11): 3100 - 3105. [Abstract] [Full Text] [PDF]

				V. Gandhi, W. Plunkett, S. Weller, M. Du, M. Ayres, C. O. Rodriguez Jr, P. Ramakrishna, G. L. Rosner, J. P. Hodge, S. O'Brien, et al. Evaluation of the Combination of Nelarabine and Fludarabine in Leukemias: Clinical Response, Pharmacokinetics, and Pharmacodynamics in Leukemia Cells J. Clin. Oncol., April 15, 2001; 19(8): 2142 - 2152. [Abstract] [Full Text] [PDF]

				D. F. Kisor, W. Plunkett, J. Kurtzberg, B. Mitchell, J. P. Hodge, T. Ernst, M. J. Keating, and V. Gandhi Pharmacokinetics of Nelarabine and 9-Beta-D-Arabinofuranosyl Guanine in Pediatric and Adult Patients During a Phase I Study of Nelarabine for the Treatment of Refractory Hematologic Malignancies J. Clin. Oncol., March 1, 2000; 18(5): 995 - 995. [Abstract] [Full Text] [PDF]

				C. O. Rodriguez Jr. and V. Gandhi Arabinosylguanine-induced Apoptosis of T-Lymphoblastic Cells: Incorporation into DNA Is a Necessary Step Cancer Res., October 1, 1999; 59(19): 4937 - 4943. [Abstract] [Full Text] [PDF]